Cannabis Report
Home > Boards > US Listed > Medical - Healthcare >

Acasti Pharma, Inc (ACST)

ACST RSS Feed
Add ACST Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 6/15/2018 12:38:53 AM - Followers: 39 - Board type: Free - Posts Today: 0

Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre®, for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one-third of the U.S. population.

Established in August 2008, Acasti is focused on addressing an important market need for an effective, safe and well-absorbed omega-3 therapeutic that can address a patient’s lipid profile — making a positive impact on the major lipids associated with cardiovascular disease risk.


 
 


President and CEO 
Jan D'Alvise
LinkedIn


 

Acasti’s Phase 3-ready investigational candidate CaPre® will be the first pharmaceutical omega-3 product sourced from krill oil. CaPre® has successfully completed phase 1 and 2 trials for the treatment of hypertriglyceridemia, a common metabolic condition characterized by high levels of triglycerides in the blood stream.

The American Heart Association has estimated that one-third of the U.S. population has elevated levels of triglycerides.

 

CaPre’s concentrated omega-3s from krill oil are absorbed into the body more efficiently than those from fish oils, enhancing bioavailability and providing benefits to a patient’s total lipid profile. That means that CaPre® doesn’t just lower triglycerides; it also has shown in clinical trials to have beneficial effects on “good” and “bad” cholesterol levels that affect heart health.
 


Laval, Québec, CANADA, Sept. 14, 2016 Acasti Pharma (NASDAQ:ACST TSX-V:APO) today announced that its bridging study for novel drug candidate CaPre® (omega-3 phospholipid) has successfully met its objectives, supporting Acasti’s strategy to pursue the U.S. Food and Drug Administration’s (FDA) 505(b)(2) regulatory pathway for approval. Acasti is developing CaPre for the treatment of patients with severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis. The 505(b)(2) regulatory pathway allows Acasti to streamline the overall development program required to support a New Drug Application (NDA) by relying on the safety data of an approved drug. 



Laval, Québec, CANADA, October 26, 2016 — Acasti Pharma (NASDAQ:ACST TSX-V:APO) today announced that the United States Patent and Trademark Office issued Acasti a patent (U.S. patent no. 9,475,830) directed to a method of treating hypertriglyceridemia by the administration of a concentrated phospholipid composition. 
This newly issued patent expands Acasti’s intellectual property portfolio related to concentrated therapeutic phospholipid omega-3 compositions covering methods for treating or preventing diseases associated with or related to cardiovascular disease. 

 
 


 







Cannabis Report
ACST
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ACST News: Report of Foreign Issuer (6-k) 07/02/2018 06:27:10 PM
ACST News: Acasti Pharma Announces Annual Performance Grants of Stock Options, Amendment of Stock Option Plan and Issuance of Common Sha... 07/02/2018 05:00:00 PM
ACST News: Annual and Transition Report (foreign Private Issuer) (20-f) 06/29/2018 11:40:11 AM
ACST News: Report of Foreign Issuer (6-k) 06/27/2018 05:29:35 PM
ACST News: Report of Foreign Issuer (6-k) 06/27/2018 05:03:33 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#430   drug and vitamin combo shurtha2000 06/15/18 12:38:53 AM
#429   * * $ACST Video Chart 06-14-18 * * ClayTrader 06/14/18 04:10:46 PM
#428   BREAKING $1 SOON @THEPENNYWOLF 05/22/18 03:56:08 PM
#427   OUCH ..!!! Should have sold this POS three caloosa 04/24/18 04:28:26 PM
#426   ACST announces $1.05 pricing of offering https://finance.yahoo.com/news/acasti-pharma-prices-10-mill [SMART MONEY] 04/24/18 01:01:55 PM
#425   No. It is not dilution like a regular I.B.Broke 04/24/18 05:38:09 AM
#424   So bad thing? tabuhasna 04/24/18 05:33:23 AM
#423   $ACST The halt is unusual for an offering. I.B.Broke 04/24/18 05:32:44 AM
#422   What’s your take on the halt? tabuhasna 04/24/18 05:05:04 AM
#421   $ACST Stake Lifted by Virtu Financial LLC I.B.Broke 04/15/18 12:06:08 PM
#420   Not much going on here .... caloosa 04/13/18 12:47:53 PM
#419   ACST: Heavy Volume 500k so far Up 12.58% caloosa 04/02/18 10:16:31 AM
#418   Happy Easter ... caloosa 03/29/18 02:51:54 PM
#417   No news ,very quiet ... caloosa 03/27/18 12:24:12 PM
#416   $ACST yeah, I was surprised by the spike I.B.Broke 03/18/18 03:22:28 PM
#415   Very good volume ,473,004 News soon IMHO . caloosa 03/18/18 02:01:30 PM
#414   Acasti Pharma Announces First Patient Randomized in Pivotal I.B.Broke 03/14/18 08:37:22 AM
#413   The pps should only change when the shares I.B.Broke 03/08/18 08:20:07 PM
#412   What is your thoughts on it now? tabuhasna 03/08/18 06:15:19 PM
#411   Meanwhile PPS going down ... caloosa 03/05/18 09:05:37 AM
#410   That is because of the board of director’s situation. I.B.Broke 03/04/18 06:31:36 PM
#409   ACST :I with TD Ameritrade and i have caloosa 03/04/18 02:35:21 PM
#408   EU patent still under review. investorshub.advfn.com/uimage/uploads/2018/ I.B.Broke 03/04/18 11:50:13 AM
#407   Agree. All it was was a heads up. PJO 03/01/18 11:08:12 AM
#406   Yea but that takes months it’s not as tabuhasna 03/01/18 11:06:20 AM
#405   Yes I also looked for other announcements and PJO 03/01/18 10:54:14 AM
#404   I use Fidelity Active trader pro. When you PJO 03/01/18 10:49:57 AM
#403   He’s trying to get in lower than a tabuhasna 03/01/18 10:06:55 AM
#402   Where do u see this? I Need Money 03/01/18 07:18:00 AM
#401   Failed to meet NASDAQ continued listing requirments message PJO 02/28/18 11:07:23 AM
#400   Took a few under a buck this week. I Need Money 02/24/18 06:50:24 AM
#399   I wonder if the Asian company is with GM26 02/13/18 09:27:37 PM
#398   If a definitive agreement is reached and signed, GM26 02/13/18 09:21:32 PM
#397   $ACST Points from the third quarter fiscal year I.B.Broke 02/13/18 08:10:47 PM
#396   In both Phase 2 clinical trials, CaPre significantly I.B.Broke 02/04/18 01:25:29 PM
#395   Dawson James’ Coverage Initiation Report on $ACST I.B.Broke 02/03/18 12:13:28 PM
#394   1/28/18 The phase 3 trials started the recruiting I.B.Broke 02/01/18 08:30:05 PM
#393   Nice and easy does it all the time caloosa 01/23/18 07:12:18 PM
#392   Very solid upturn. Next stop....$2. $ACST I.B.Broke 01/23/18 06:54:02 PM
#391   Another very good day, getting better and better $$$ caloosa 01/23/18 12:57:01 PM
#390   The best is yet to come. $$$ caloosa 01/23/18 07:52:56 AM
#389   It was a good day. Still holding a $oldier Hard 01/22/18 11:49:24 PM
#388   $ACST Stayed strong all day. I.B.Broke 01/22/18 03:52:06 PM
#387   Up Pre-Market ..$$$ caloosa 01/22/18 08:58:26 AM
#386   No news. I removed that post because after I.B.Broke 01/18/18 11:31:00 AM
#385   What kind news tomorrow????????? Cheers PJO 01/18/18 11:19:17 AM
#383   ACST..$$$ Going North $$$ caloosa 01/17/18 04:15:47 PM
#382   ACST Will be a Blockbuster $$$$$ caloosa 01/17/18 10:24:30 AM
#381   Arrow Capital Management portfolio manager Alex Ruus discusses I.B.Broke 01/17/18 10:08:06 AM
#380   $ACST on the move up pre-market I.B.Broke 01/17/18 09:30:03 AM
PostSubject